Baron Wealth Management LLC Invests $347,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Baron Wealth Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 3,759 shares of the biopharmaceutical company’s stock, valued at approximately $347,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth about $25,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Friedenthal Financial purchased a new position in Gilead Sciences in the third quarter worth approximately $50,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on GILD shares. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Truist Financial increased their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Read Our Latest Report on Gilead Sciences

Gilead Sciences Stock Up 1.9 %

GILD opened at $95.59 on Thursday. The business has a 50 day moving average price of $92.00 and a two-hundred day moving average price of $85.44. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a market cap of $119.13 billion, a PE ratio of 1,062.11, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.